CGF Treatment of Leg Ulcers: a Randomized Controlled Trial

Abstract Background Concentrated Growth Factors (CGF) is a concentration of second generation autologous growth factors compared to platelet rich plasma (PRP) and represents a multifactorial stimulation system that can be used for the management and treatment of chronic skin ulcers. Aim The aim of this work is to evaluate the additional benefits of the CGF compared to the standard of dressing and its effects on the dynamics of the healing process. Methods Autologous CGFs were obtained from 100 patients with chronic mixed ulcers (venous ulcers in patients with II stage claudication) of the lower limbs in a multicentric controlled randomized study. Results The results showed a significant advantage in the use of CGF in association with cleansing and selective compression in the healing time and stabilization of mixed ulcers of the lower extremities. Conclusions These results support the CGF’s clinical use for improving clinical outcomes in mixed ulcers of the legs.

[1]  J. Brittenden,et al.  Extracorporeal shock wave therapy for the healing and management of venous leg ulcers , 2015 .

[2]  R. Serra,et al.  From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases , 2017, International wound journal.

[3]  R. Serra,et al.  The role of adult tissue‐derived stem cells in chronic leg ulcers: a systematic review focused on tissue regeneration medicine , 2016, International wound journal.

[4]  R. Serra,et al.  PredyCLU: a prediction system for chronic leg ulcers based on fuzzy logic; part I – exploring the venous side , 2016, International wound journal.

[5]  R. Serra,et al.  Study on the efficacy of surgery of the superficial venous system and of compression therapy at early stages of chronic venous disease for the prevention of chronic venous ulceration , 2016, International wound journal.

[6]  R. Serra,et al.  Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines , 2016, International wound journal.

[7]  R. Serra,et al.  Role of matrix metalloproteinases in non‐healing venous ulcers , 2015, International wound journal.

[8]  T. Kawase,et al.  In vitro immunological and biological evaluations of the angiogenic potential of platelet-rich fibrin preparations: a standardized comparison with PRP preparations , 2015, International journal of implant dentistry.

[9]  R. Serra,et al.  Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus , 2015, Expert review of anti-infective therapy.

[10]  R. Serra,et al.  Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly , 2015, International wound journal.

[11]  P. Formisano,et al.  Growth-promoting action and growth factor release by different platelet derivatives , 2014, Platelets.

[12]  T. Kawase,et al.  A proposed protocol for the standardized preparation of PRF membranes for clinical use. , 2012, Biologicals : journal of the International Association of Biological Standardization.

[13]  L. Rodella,et al.  Growth factors, CD34 positive cells, and fibrin network analysis in concentrated growth factors fraction , 2011, Microscopy research and technique.

[14]  J. Dragoo,et al.  Comparison of Growth Factor and Platelet Concentration From Commercial Platelet-Rich Plasma Separation Systems , 2011, The American journal of sports medicine.

[15]  P. Tazzari,et al.  A recently developed bifacial platelet-rich fibrin matrix. , 2010, European cells & materials.

[16]  Y. Long,et al.  [Preparation of autologous platelet-rich gel for diabetic refractory dermal ulcer and growth factors analysis from it]. , 2008, Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery.

[17]  Gorka Orive,et al.  Delivering growth factors for therapeutics. , 2008, Trends in pharmacological sciences.

[18]  G. Orive,et al.  The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. , 2007, Biomaterials.

[19]  A. Dohan,et al.  Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. , 2006, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[20]  A. Dohan,et al.  Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV: clinical effects on tissue healing. , 2006, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[21]  M. Mosesson.  Fibrinogen and fibrin structure and functions , 2005, Journal of thrombosis and haemostasis : JTH.

[22]  B. Eppley,et al.  Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. , 2004, Plastic and reconstructive surgery.

[23]  R. Marx.  Platelet-rich plasma: evidence to support its use. , 2004, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[24]  E. Freymiller.  Platelet-rich plasma: evidence to support its use. , 2004, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[25]  T. Kawase,et al.  Platelet-rich plasma contains high levels of platelet-derived growth factor and transforming growth factor-beta and modulates the proliferation of periodontally related cells in vitro. , 2003, Journal of periodontology.

[26]  G. Hafner,et al.  Growth factor levels in the platelet-rich plasma produced by 2 different methods: curasan-type PRP kit versus PCCS PRP system. , 2002, The International journal of oral & maxillofacial implants.

[27]  B. Amato,et al.  The early effects of intravenous L-propionyl carnitine on ulcerative trophic lesions of the lower limbs in arteriopathic patients: a controlled randomized study. , 1995, Drugs under experimental and clinical research.